One of the biggest stories coming out of Transcatheter Cardiovascular Therapeutics’ annual meeting in Boston this weekend focuses on the success of Edwards Lifesciences Corp.’s freshly FDA-approved ...
Edwards Lifesciences has secured European approval for its transcatheter tricuspid valve replacement system, which the company described as the first minimally invasive therapy of its kind to receive ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
BOSTON, MA—Patients with significant symptomatic degenerative mitral regurgitation (MR) who had complex anatomy making them ineligible for inclusion in the CLASP IID trial can be treated safely and ...
A study of Edwards Lifesciences’ tricuspid valve replacement system met both its co-primary effectiveness endpoints at six months, showing its superiority to optimal medical therapy alone. Edwards ...
Abbott Laboratories (ABT) announced on Monday that it has reached an agreement with Edwards Lifesciences Corp. (EW) to settle all outstanding patent disputes related to heart valve medical devices or ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...
The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback